Discontinuation of Development Sample Clauses

Discontinuation of Development. If after completion of all Development activities under the applicable Joint Phase IIb Plan, both Parties’ representatives on the applicable JDC agree that the Development of the applicable Product Candidate in such Indication shall be discontinued, then such Product Candidate shall be discontinued as a Product Candidate for such Indication and returned to the JEC for a determination as to whether it should be: (A) re-designated as a Development Candidate for additional Exploratory Development Activities pursuant to Article 4, or (B) retained as a Product Candidate, but for another Indication to be selected by the JEC and then referred again to the JDC under this Article 5.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Discontinuation of Development. During the term of this Agreement, and for a period of ****** years thereafter, in the event Lilly desires to license or discontinue development of a CART Identified Compound or Drug Product, Lilly hereby grants to Arena a right to negotiate a license to such CART Identified Compound or Drug Product. Lilly shall provide to Arena written Notice of such desire to license or discontinue development of such CART Identified Compound or Drug Product.
Sample 1Sample 2
Discontinuation of Development. Solvay agrees to notify ArQule if it decides to discontinue development or marketing of any Licensed Compound or Derivative Compounds thereof. In addition, throughout the term of this Agreement, Solvay will submit to ArQule annual written reports and semi-annual verbal reports of the activities of Solvay and its Affiliates with respect to all such compounds during the reporting period. These reports will include relevant chemical and biological data and other information sufficient to allow ArQule to determine whether Solvay and/or its Affiliates are engaging in significant activity with respect to each such compound prior to Project Declaration. The information in such reports shall be considered Confidential Information under Section 10.1. hereof. During the Research Period, Solvay shall provide such reports on a schedule such that they can be reviewed at the meetings of the Research Committee. In addition, Solvay agrees to inform ArQule at least once each calendar year regarding the status of any Solvay Derivative Compounds that Solvay develops based on Solvay Derivative Compounds synthesized by ArQule under this Agreement.
Sample 1Sample 2
Discontinuation of Development. In the event Amgen shall at any time elect to discontinue all development and commercialization activities relating to Licensed Products, Amgen will notify Progenitor in writing of such election and upon Progenitor's receipt of such notification, this Agreement will terminate and all licenses under the Licensed Patents granted to Amgen and its Affiliates hereunder will revert to Progenitor.
Sample 1Sample 2
Discontinuation of Development. If the JSC determines to discontinue Developing a Licensed Product upon recommendation by the JDC, the Development Plan for such Licensed Product shall terminate upon such decision. Upon such determination by the JSC, the JSC shall remove such Named Compound or the relevant Named Indication(s) from Schedule 1.65 or 1.66, as applicable, pursuant to Section 4.1.2(e) at its next scheduled meeting (which in any event shall be no later than three (3) months after such determination) unless there is a Development Plan or Commercialization Plan for any Licensed Product with respect to such Named Compound or such Named Indication in effect at such time of such JSC determination or unless otherwise agreed to by the Parties.
Sample 1
Discontinuation of Development. In the event that Celgene fails to develop at least one Licensed Product pursuant to Section 3.1, then Celgene agrees to negotiate in good faith with CMCC to sublicense under commercially reasonable terms a Licensed Product to a third party.
Sample 1
Discontinuation of Development. If SANKYO discontinues development of all Compounds pursuant to the Research Program then SANKYO shall immediately notify OSI thereof and OSI shall have the sole and exclusive right, subject to the payment of royalties as set forth in this Article 2.4.2, to pursue development of any and all Compounds, and to develop, make, have made, use, and sell Products containing any Compound, provided, however, this clause shall not apply to any Compound which SANKYO has included in a sub-license to a third party prior to its decision to discontinue development of all Compounds. No royalties, milestone payments or any other payments shall be payable by OSI to the other parties hereto with respect to such Compounds; provided, however, that (i) OSI shall pay to SANKYO a royalty at the rate of ** of the Net Sales of OSI for each Product derived from such Compound, the manufacture, use or sale of which is covered by a Valid Claim of the Patent Rights, which royalty OSI shall continue to pay in each applicable country until the expiration of the last Valid Claim under the Patent Rights applicable to such Product expires in such ----------------------- ** This portion redacted pursuant to a request for confidential treatment.
Sample 1
AutoNDA by SimpleDocs
Discontinuation of Development. If the Committee decides to discontinue Developing a ThermoDox Product, the Development Plan for such ThermoDox Product shall immediately terminate upon such decision. Upon such determination by the Committee, the Committee shall remove such Named Indication(s) from Schedule 1.53 unless otherwise agreed to by the Parties.
Sample 1
Discontinuation of Development. Solvay Duphar agrees to notify ArQule if it decides to discontinue development or marketing of any Active ArQule Compound or Derivatives thereof. In addition, throughout the term of this Agreement, Solvay Duphar will submit to ArQule quarterly reports of the activities of Solvay Duphar and its Affiliates with respect to all such compounds during the prior three-month period. These reports will include relevant chemical and biological data and other information sufficient to allow ArQule to determine whether Solvay Duphar and/or its Affiliates are engaging in significant activity with respect to each such compound prior to Project Declaration. The information in such reports shall be considered Confidential Information under Section 10.1. hereof. During the Research Period, Solvay Duphar shall provide such reports on a schedule such that they can be reviewed at the quarterly meetings of the Research Committee.
Sample 1

Related to Discontinuation of Development

  • Completion of Development 7.4.1 Upon the completion of the whole development or complete phases of the development, Council may review this Agreement, in whole or in part, and may: (a) retain the Agreement in its present form; (b) negotiate a new Agreement; (c) discharge this Agreement; or (d) for those portions of the development which are completed, discharge this Agreement and apply appropriate zoning pursuant to the Municipal Planning Strategy and Land Use By-law for Halifax Peninsula as may be amended from time to time.

  • Commencement of Development 5.3.1 In the event that development on the Lands has not commenced within five (5) years from the date of registration of this Agreement at the Registry of Deeds or Land Registry Office, as indicated herein, the Agreement shall have no further force or effect and henceforth the development of the Lands shall conform with the provisions of the Land Use By-law. For the purpose of this section, commencement of development shall mean issuance of a Mobile Home Park Construction Permit. 5.3.2 For the purpose of this section, Council may consider granting an extension of the commencement of development time period through a resolution under Section 4.1 of this Agreement, if the Municipality receives a written request from the Developer at least sixty (60) calendar days prior to the expiry of the commencement of development time period.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Staff Development ‌ The County and the Association agree that the County retains full authority to determine training needs, resources that can be made available, and the method of payment for training authorized by the County. Nothing in this subsection shall preclude the right of an employee to request specific training.

  • Notice of Developments Each Party will give prompt written notice to the other of any material adverse development causing a breach of any of its own representations and warranties in Section 3 and Section 4 above. No disclosure by any Party pursuant to this Section 5(f), however, shall be deemed to amend or supplement the Disclosure Schedule or to prevent or cure any misrepresentation, breach of warranty, or breach of covenant.

  • Subsequent Developments After the date of this Contract and until the Closing Date, Seller shall use best efforts to keep Buyer fully informed of all subsequent developments of which Seller has knowledge (“Subsequent Developments”) which would cause any of Seller’s representations or warranties contained in this Contract to be no longer accurate in any material respect.

  • Assignment of Developments (i) Executive acknowledges and agrees that all developments, including, without limitation, the creation of new products, devices, inventions, discoveries, concepts, ideas, improvements, patents, trademarks, trade names, trade dress, service marks, copyrights, domain names, trade secrets, designs, works, reports, computer software or systems, flow charts, diagrams, procedures, data, documentation, and writings and applications thereof, including all results and proceeds of the foregoing, relating to the Business or future business of the Company that Executive, alone or jointly with others, has discovered, suggested, conceived, created, made, developed, reduced to practice, or acquired during Executive’s employment with or as a result of Executive’s employment with the Company (collectively, “Developments”) are being prepared by Executive as an employee of the Company within the scope of Executive’s employment and shall be considered as “works made for hire” and shall remain the sole and exclusive property of the Company, free of any reserved or other rights of any kind on Executive’s part. If and to the extent the fact that the Developments are works made for hire is not effective to place ownership of the Developments and all rights therein to the Company, then Executive hereby solely, exclusively and irrevocably assigns and transfers to the Company any and all of his right, title and interest in and to the Developments. Executive agrees to disclose to the Company promptly and fully all future Developments and, at any time upon request and at the expense of the Company, to execute, acknowledge and deliver to the Company all instruments that the Company shall prepare and to take any and all other actions that are necessary or desirable, in the reasonable opinion of the Company, to evidence or effectuate all or any of the Company’s rights hereunder, including executing and delivering patent, trademark or copyright applications and instruments of assignment to the Company and enabling the Company to file instruments of assignment for, to file and prosecute applications for, and to acquire, maintain, and enforce, all patents, trademarks or copyrights covering the Developments in all countries in which the same are deemed necessary by the Company. All data, memoranda, notes, lists, drawings, records, files, investor and client/customer lists, supplier lists, and other documentation (and all copies thereof) made or compiled by Executive or made available to Executive concerning the Developments or otherwise concerning the past, present, or planned business of the Company are the property of the Company, and shall be delivered to the Company immediately upon the termination of Executive’s employment with the Company. (ii) If any patent, trademark or copyright application is filed by Executive or on Executive’s behalf during Executive’s employment with the Company or within one (1) year after Executive’s leaving the Company’s employ, describing a Development within the scope of Executive’s work for the Company or which otherwise relates to a portion of the business of the Company, of which the Executive had knowledge during Executive’s employment with the Company, it is to be conclusively presumed that the Development was conceived by Executive during the period of such employment.

  • Project Development a. Collaborate with COUNTY and project clients to identify requirements and develop a project Scope Statement. a. Develop a Work Breakdown Structure (WBS) for each project. b. Evaluate Scope Statement to develop a preliminary cost estimate and determinate whether project be vendor bid or be executed under a Job Order Contract (JOC).

  • Product Development (a) Supplier may develop enhancements it intends to incorporate into the BioGlue Surgical Adhesive during the term of this Agreement that have potential application to the Company Product (“Enhancements”). Unless otherwise agreed by the parties, at least once every six months during the Term, representatives of each of BioForm and Supplier shall hold a meeting in accordance with Sections 4.4 and 8.4 (the “Product Development Meeting”) at which Supplier will present Enhancements for BioForm to consider for application to the Company Product. At such Product Development Meeting, BioForm will also present its marketing plans (pursuant to Section 4.4) for the period and any information or feedback that BioForm reasonably believes may lead to Improvements. Within 30 calendar days following each Product Development Meeting, Supplier shall deliver a notice to BioForm (the “Enhancements Notice”) that shall describe the Enhancements that were presented by Supplier at such Product Development Meeting. Within 30 calendar days following receipt of the Enhancements Notice, BioForm may notify Supplier in writing if BioForm elects that any Enhancement described in the Enhancements Notice shall become an Improvement. If BioForm does provide such notice to Supplier during such 30-calendar day period, then BioForm and Supplier shall agree on a timeline for implementation of the Improvement in new Product Specifications for Company Product. If BioForm does not provide such a notice, said Enhancement shall not be implemented into the Company Product. The Enhancements Notice may also describe any potential Enhancements presented by Supplier at the Product Development Meeting, but BioForm shall not be required to take any action under this Section 8.4 with respect to such potential Enhancements until such time as they are presented by Supplier as Enhancements at a future Product Development Meeting. All Enhancements and potential Enhancement information provided by Supplier shall be considered Supplier Confidential Information. (b) From time to time, each party may request the other party to participate in joint projects to develop Improvements. Neither party is obligated to participate in such projects, and in each **** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. instance, each party’s decision whether to participate will be made in such party’s sole discretion. If both parties mutually agree to participate in such a project (a “Program”), the parties will promptly prepare a mutually agreeable written development agreement specifying the development activities to be performed by and the research and development tasks assigned to each party (the “Development Agreement”). All allocation of Intellectual Property rights with respect to any Program will be set forth in writing in the Development Agreement. (c) In the absence of a Development Agreement, (i) BioForm and Supplier shall retain joint ownership of Intellectual Property rights in which there is joint inventorship by BioForm (or its Affiliates) and Supplier, as determined in accordance with United States patent law, with Supplier’s rights in such joint ownership being subject to the license rights of BioForm under this Agreement, (ii) any Intellectual Property rights related to the Company Products, Enhancements, and Improvements that are created solely by employees or consultants of Supplier during the Term shall be considered to be Intellectual Property rights of Supplier, subject to the license rights of BioForm under this Agreement, and (iii) any Intellectual Property rights related to the Company Products and Improvements that are created solely by employees or consultants of BioForm or any of its Affiliates during the Term shall be considered to be Intellectual Property rights of BioForm. BioForm hereby grants to Supplier a perpetual, royalty free, world-wide, nonexclusive license to Supplier under such Blocking Intellectual Property to make, use, and sell such Intellectual Property outside the Field. “Blocking Intellectual Property” for the purposes of Section 8.4(c)(iii) shall mean Intellectual Property necessary for Supplier to make, use, or sell SA Product.

  • Career Development The City and the Union agree that employee career growth can be beneficial to both the City and the affected employee. As such, consistent with training needs identified by the City and the financial resources appropriated therefore by the City, the City shall provide educational and training opportunities for employee career growth. Each employee shall be responsible for utilizing those training and educational opportunities made available by the City or other institutions for the self- development effort needed to achieve personal career goals.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!